1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2020, provides an overview of the Neuroendocrine Tumors (Oncology) pipeline landscape.
Neuroendocrine tumor begins in the hormone-producing cells of the body’s neuroendocrine system, which is made up of cells that are a cross between traditional endocrine cells (or hormone-producing cells) and nerve cells. Symptom includes hyperglycemia, diarrhea, loss of appetite/weight loss, thickening or lump in any part of the body, jaundice, headache, anxiety and gastric ulcer disease. Treatments include surgery, radiation therapy and chemotherapy.
Report Highlights
The publisher's Pharmaceutical and Healthcare latest pipeline guide Neuroendocrine Tumors - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Neuroendocrine Tumors (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Neuroendocrine Tumors (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Neuroendocrine Tumors and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 34, 29, 1, 11, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Discovery stages comprises 1, 3 and 1 molecules, respectively.
Neuroendocrine Tumors (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Neuroendocrine Tumors (Oncology).
- The pipeline guide reviews pipeline therapeutics for Neuroendocrine Tumors (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Neuroendocrine Tumors (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Neuroendocrine Tumors (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Neuroendocrine Tumors (Oncology)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuroendocrine Tumors (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuroendocrine Tumors (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Neuroendocrine Tumors - Overview
- Neuroendocrine Tumors - Therapeutics Development
- Neuroendocrine Tumors - Therapeutics Assessment
- Neuroendocrine Tumors - Companies Involved in Therapeutics Development
- Neuroendocrine Tumors - Drug Profiles
- Neuroendocrine Tumors - Dormant Projects
- Neuroendocrine Tumors - Discontinued Products
- Neuroendocrine Tumors - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Neuroendocrine Tumors, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Products under Development by Companies, H1 2020
- Products under Development by Universities/Institutes, H1 2020
- Number of Products by Stage and Target, H1 2020
- Number of Products by Stage and Mechanism of Action, H1 2020
- Number of Products by Stage and Route of Administration, H1 2020
- Number of Products by Stage and Molecule Type, H1 2020
- Neuroendocrine Tumors - Pipeline by Aadi Bioscience Inc, H1 2020
- Neuroendocrine Tumors - Pipeline by Advanced Accelerator Applications SA, H1 2020
- Neuroendocrine Tumors - Pipeline by Akeso Inc, H1 2020
- Neuroendocrine Tumors - Pipeline by AnHeart Therapeutics Inc, H1 2020
- Neuroendocrine Tumors - Pipeline by Aquestive Therapeutics Inc, H1 2020
- Neuroendocrine Tumors - Pipeline by Ascil Proyectos SL, H1 2020
- Neuroendocrine Tumors - Pipeline by AstraZeneca Plc, H1 2020
- Neuroendocrine Tumors - Pipeline by Beijing Foreland Pharma Co Ltd, H1 2020
- Neuroendocrine Tumors - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
- Neuroendocrine Tumors - Pipeline by BriaCell Therapeutics Corp, H1 2020
- Neuroendocrine Tumors - Pipeline by Bristol-Myers Squibb Co, H1 2020
- Neuroendocrine Tumors - Dormant Projects, H1 2020
- Neuroendocrine Tumors - Discontinued Products, H1 2020
List of Figures
- Number of Products under Development for Neuroendocrine Tumors, H1 2020
- Number of Products under Development by Companies, H1 2020
- Number of Products under Development by Universities/Institutes, H1 2020
- Number of Products by Top 10 Targets, H1 2020
- Number of Products by Stage and Top 10 Targets, H1 2020
- Number of Products by Top 10 Mechanism of Actions, H1 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
- Number of Products by Top 10 Routes of Administration, H1 2020
- Number of Products by Stage and Top 10 Routes of Administration, H1 2020
- Number of Products by Top 10 Molecule Types, H1 2020
- Number of Products by Stage and Top 10 Molecule Types, H1 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aadi Bioscience Inc
- Advanced Accelerator Applications SA
- Akeso Inc
- AnHeart Therapeutics Inc
- Aquestive Therapeutics Inc
- Ascil Proyectos SL
- AstraZeneca Plc
- Beijing Foreland Pharma Co Ltd
- Boehringer Ingelheim International GmbH
- BriaCell Therapeutics Corp
- Bristol-Myers Squibb Co
- Camurus AB
- CanBas Co Ltd
- Clarity Pharmaceuticals Pty Ltd
- Crinetics Pharmaceuticals Inc
- Dauntless Pharmaceuticals Inc
- DexTech Medical AB
- Eli Lilly and Co
- Enterome Bioscience SA
- EpicentRx Inc
- Esanex Inc
- Esperance Pharmaceuticals Inc
- Exelixis Inc
- GEMoaB Monoclonals GmbH
- HEC Pharm Co Ltd
- Highlight Therapeutics SL
- Hutchison MediPharma Ltd
- Innovent Biologics Inc
- INVENT Pharmaceuticals Inc
- Ipsen SA
- Jubilant DraxImage Inc
- Karyopharm Therapeutics Inc
- Lexicon Pharmaceuticals Inc
- Lixte Biotechnology Holdings Inc
- Mateon Therapeutics Inc
- Merck & Co Inc
- Merck KGaA
- Millennium Pharmaceuticals Inc
- MimiVax LLC
- Mina Therapeutics Ltd
- Molecular Targeting Technologies Inc
- Molecular Templates Inc
- Nanovalent Pharmaceuticals Inc
- Northwest Biotherapeutics Inc
- Novartis AG
- Oncoceutics Inc
- Oncology Venture U.S. Inc
- Ono Pharmaceutical Co Ltd
- Orano Med LLC
- Pfizer Inc
- Pharma Mar SA
- Pharmathen Global BV
- Progenics Pharmaceuticals Inc
- Provectus Biopharmaceuticals Inc
- Regulaxis SAS
- Rhizen Pharmaceuticals SA
- Seneca Therapeutics Inc
- Shanghai Junshi Bioscience Co Ltd
- Sichuan Huiyang Life Science and Technology Corp
- Strongbridge Biopharma plc
- Suntec Medical (Taiwan) Inc
- Taiho Oncology Inc
- Tarveda Therapeutics Inc
- Teclison Ltd
- Trio Medicines Ltd
- Vanquish Oncology Inc
- Veana Therapeutics LLC
- Vyriad Inc
- Xencor Inc
